evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

96 questions · 97 findings · 33 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 29 · 29.9%GRADE not reported 4 · 4.1%Very low 28 · 28.9%Low 28 · 28.9%Moderate 7 · 7.2%High 1 · 1%

Thrombo‐aspiration alone vs stent‐retrieval thrombectomy alone

All‐cause mortality within 3 months · people with acute ischemic stroke

Thrombo‐aspiration alone showed no clear difference in all‐cause mortality within 3 months compared with stent‐retrieval thrombectomy alone (high certainty).

1 finding from 1 review

Intravenous tranexamic acid vs placebo

All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures

Intravenous tranexamic acid showed no clear difference in all‐cause mortality (30 days post‐surgery) compared with placebo (low certainty).

1 finding from 1 review

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs placebo

All‐cause mortality (30 days post‐surgery) · people undergoing definitive fixation of hip, pelvic and long bone fractures

It is very uncertain whether topical tranexamic acid changes all‐cause mortality (30 days post‐surgery) compared with placebo (very low certainty).

1 finding from 1 review

Glutamine vs placebo

All‐cause mortality at 100 days post‐transplant · People undergoing stem cell transplant with haematological malignancies

It is very uncertain whether summary of findings: Glutamine changes all‐cause mortality at 100 days post‐transplant ( compared with placebo (very low certainty).

1 finding from 1 review

Ursodeoxycholic acid vs placebo or no treatment

All‐cause mortality at 100 days post‐transplant · Patients undergoing stem cell transplant with malignant and non‐malignant diseases

Summary of findings: Ursodeoxycholic acid may leads to lower all‐cause mortality at 100 days post‐transplant ( compared with placebo or no treatment (low certainty).

1 finding from 1 review

Heparin vs no treatment

All‐cause mortality at 100 days post‐transplant · People undergoing autologous or HLA identical allogeneic bone marrow transplant with a variety of malignant diseases or aplastic anaemia

Summary of findings: Heparin showed no clear difference in all‐cause mortality at 100 days post‐transplant ( compared with no treatment (low certainty).

1 finding from 1 review

Pharmacological treatment vs pharmacological treatment 2

All‐cause mortality ‐ short term (end of treatment) · health problem or population

It is very uncertain whether summary of findings table ‐ Pharmacological treatment 1 changes all‐cause mortality ‐ short term (end of treatment) compared with pharmacological treatment 2 (very low certainty).

1 finding from 1 review

Exercise vs control

All‐cause mortality at end of intervention (range 2–10 months) · adult patients after liver transplantation.

It is very uncertain whether exercise changes all‐cause mortality at end of intervention (range 2–10 months) compared with control (very low certainty).

1 finding from 1 review